A Type II Diabetes drug developed by French drug maker Sanofi-Aventis showed promising results in a GetGoal-X Phase III study. The results showed that the drug, lixisenatide, resulted in a reduction in HbA1c, an important marker for average blood glucose concentration. Furthermore, participants who were taking lixisenatide had fewer hypoglycemic events in comparison to exenatide, a drug currently on the market to treat Type II Diabetes.
Lixisenatide belongs to a class of drugs known as GLP-1 receptor agonists. This means that the drug mimics the actions of the GLP-1 protein that is produced by our bodies. In the body, GLP-1 is released almost immediately following a meal. Among it’s many known actions, GLP-1 increases insulin secretion by beta cells in the pancreas. Due to it’s ability to mimic the actions of GLP-1, lixinsenatide and other GLP-1 agonists are being developed as add-on treatments for people with Type II Diabetes.
Here at the Canadian Centre for Clinical Trials, we have several Type II Diabetes trials currently ongoing. One of them is a trial comparing linagliptin to a drug in the sulfonylurea family. Linagliptin has been shown to inhibit a protein, namely DPP-4, that acts on the same pathway as GLP-1. On the other hand, DPP-4 has been shown to decrease the action of GLP-1. By introducing an inhibitor such as linagliptin into the blood stream, the beta cells in the pancreas are able to secrete more insulin, thereby helping to treat high blood glucose levels that diabetic patients have to deal with. This current study aims to identify if patients at high risk for cardiovascular disease benefit from receiving linagliptin versus the sulfonylurea drug.
The results of these trials may prove crucial in advancing our understanding of diabetes and help improve current treatment regimens.
For more information or to see if you are eligible for any of our current Type II Diabetes trials (or other trials), visit: https://clinicaltrialscanada.clinicalconductor.com/CCEWEB/Forms/frmUserView.aspx
Or contact us via:
Telephone: (289) 597-0106